公司資料
Orphazyme 股價、新聞與催化劑
- 股票代碼:
- ORPH
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Denmark and traded in the U
股價為何變動
Current closing-price context is not available for ORPH.
公司概覽
業務概覽
Orphazyme was a CNS-focused biotechnology company built around heat-shock protein biology and rare disease neuroscience programs. Its narrative was centered on difficult neurologic conditions where even modest clinical signals could matter, but the company ultimately became a historical small-cap biotech name.
所在地與產業分類
Orphazyme was based in Denmark and traded in the U.S. as an ADR, giving it a cross-border biotechnology profile. It belonged to the rare-disease and neuroscience development segment rather than commercial pharma.
商業模式特徵
The business model was defined by clinical development, regulatory uncertainty, and the challenge of financing a narrow pipeline. Investors historically watched proof-of-concept data and whether the company could translate biology into an approvable asset.
生技產業定位
Orphazyme sits in the historical bucket of high-risk CNS biotech names. It is best understood as a cautionary example of how difficult rare-disease neuroscience development can be for a small public company.
未來催化劑
- Orphazyme is a legacy / closeout story now, so the catalysts are any remaining resolution update rather than a pipeline event. The market is focused on residual value.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。